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Introduction
Neurodegenerative disease (ND) is a special and complex 
concept presenting much different from other systematic 
diseases including infection, immune, nutrition insufficiency, 
hypoxia, etc. It may clinically present as a disorder or disability 
with partial congenital relationships, and involve inflammatory 
patterns including lymphocyte infiltration in pathological findings 
with metabolic origins. In the cellular point of  view, neurons 
cannot exist alone and need surrounding supports including 
glial cells and blood supply. Furthermore, the neural system is a 
complete network, and some specific pathological changes may 
result in the next or previous connections, which may increase 
difficulties in the primary and secondary disease determinations.
Some neurodegenerative diseases involve in cortex, basal 
ganglia, cerebellum, or spinal cord, while others may occur in 
the intermediate form or multi-systemic diseases. Despite of  the 
complexity, most of  the neurodegenerative diseases present in 
neuron decrease or even disappear with glial cell occupations in 
the later stages.
Abstract
Neurodegenerative disease (ND) is a complex concept involves multiple pathogenesis including neuronal demyelination, 
apoptosis under oxidative stress, neuroinflammation with further cortical and spinal atrophy, which may lead to cognition 
impairment and multiple neural dysfunctions. It may present as a chronic and irreversibly progressive disorder and shows 
the common pathological pictures among its various types including Alzheimer’s disease (AD), Parkinson’s disease (AD), 
Huntington’s disease (HD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS). The symptoms often occur 
among the elderly above 50 years old and last from years to decades. Such facts lead ND as the highest priority to geriatrics 
and its related medical care. Due to its chronic progressively characteristics, regularly invasive procedure arrangements may 
face the difficulty and regarded as unbearable in the clinical practice. Unfortunately, current available therapy is mainly on 
symptom relief  and the potential therapeutic targets may focus on the macromolecules including oligomer, peptides, or 
even functional proteins with the quaternary structure since multiple proteinopathy involvement in ND pathogenesis. Such 
macromolecular administrations cause the challenges in the routine drug delivery selections due to the impossibility of  the 
traditional oral intake.
Intra-maxillary molecular releasing is a newly drug delivery pathway via dental implant and may directly reach the inside 
bone marrow. It presents the advantages in long-term and continuous macromolecular releasing with relative painless pro-
cess, which is appropriate for further applications in ND therapeutics. The stability of  dental implant inside the oral cavity 
has also been proved for decades among more than millions around the world. However, such delivery pathway is cur-
rently under development and further interdisciplinary investigations are needed including therapeutics, pharmacokinetics, 
neurology, molecular biology, clinical dentistry, chemical engineering, automatics and further complementary metal-oxide-
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Alzheimer’s disease (AD)
AD is the most common neurodegenerative disorder among 
the elderly above fifty years old [1]. It affects 10% of  the elderly 
above 65 years old, and around half  of  those over 85 years old 
[2, 3]. The typical symptoms include memory loss, cognitive 
impairment, and behavior dysfunctions. It may also induce 
secondary physiological dysfunctions including swallowing, and 
psychological involvement such as depression [4, 5]. The etiology 
of  AD remains unclear due to its complex and multifactorial 
pathogenesis including genetic mutation [6, 7], abnormal protein 
procession, deposition, and aggregations [8, 9], inflammation and 
related immune responses [10-12], neurotrophic factors [13, 14], 
metabolic disorders [15-17], oxidative stress [18, 19], excitotoxicity 
[20, 21], and neurotransmitter maladjustment [22, 23].
In the pathological point of  view, it may involve hippocampus 
and cortex regions with the following patterns:
1. Brain atrophy: With the neuron disappear, the brain weight 
may decrease and the sulcus is widening with ventricle 
enlargement.
2. Senile plaque: It may occur in the cortex and hippocampus, or 
even found in the basal ganglia and brain stem. In hematoxylin 
and eosin (H&E) stain histology, it represents in eosinophilic 
round shape sized about 50 μm within an amyloid center 
[24]. The amyloid is mainly from the misfolded amyloid 
β proteins (Aβ), which is a 39-43 amino acid peptide with 
β-sheet conformation leading to neurodegeneration [25]. 
Various Aβ isoforms are determined including Aβ39-Aβ43, 
while Aβ40 and Aβ42 are the most common peptides inside 
the neurotoxic soluble oligomers or insoluble fibrils arising 
neuron damages [26-30].
3. Neurofibrillary tangle (NFT): NFT is composed by the paired 
helical filaments (PHF) with 7-9 diameter twisted each other 
and forms a tangle within 80 μm [31, 32]. The PHF contains 
neurofilament tripeptide, neurotubules, Aβ, and tau protein. 
Tau protein is a microtubule-associated protein promoting its 
assembly to maintain axonal dynamics in a neuron [33, 34]. 
Currently NFT has been the key characteristics in pathology 
for AD diagnosis [35]. However, tau and NFT may be found 
not only in AD but among various ND and regarded as 
tauopathies [36]. It may be responsible for the primary origin 
to induce neurodegeneration generally, while it is regarded as 
the secondary event following amyloidogenesis in AD [37].
The above pathological findings may plot the characteristics of  AD. 
Furthermore in the molecular level, NFT may have neural toxicity 
by reducing microtubule stability due to tau protein mutation, 
hyperphosphorylation, and aggregations [38, 39]. The human tau 
gene locates on chromosome 17 with 16 exons and produces six 
isoforms by different ways of  splicing within two inserts closed 
to the N-terminus, and three to four highly conserved, imperfect 
repeat sequences microtubule-binding domains in the C-terminus 
[40, 41]. Such splicing produces two groups of  tau isoforms 
including three (3R) or four (4R) microtubule-binding repeats. In 
normal human brain, the 3R:4R tau ratio is around 1:1, while it 
may increase during neurodegenerative tauopathies [42]. There 
are two major mutations that will result in tau aggregations into 
NFTs including intronic and coding mutations [43, 44]. Besides, 
tau phosphorylation is important in its microtubule-binding 
process, and insoluble, highly phosphorylated tau may arouse 
tauopathy and leads to neuronal loss [45]. That implies inhibition 
of  protein kinases by targeting tau phosphorylation process may 
provide the therapeutic approach to reduce tau aggregations [46].
Current therapeutics of  AD is mainly for progression decelerated. 
Acetylcholinesterase (AChE) inhibitors may provide cognitive 
enhancement. Donepezil, galantamine and rivastigmine may 
enhance cholinergic neurotransmission for mild-to-moderate 
AD [47, 48], while N-methyl-D-aspartate (NMDA) receptor 
antagonist memantine is recommended for moderate-to-severe 
AD [49, 50].
Parkinson disease (PD)
PD is the second common ND and first described by James 
Parkinson [51]. It is a progressive neurological motor dysfunction 
involves extrapyramidal system, and leads to tremors with hands 
and jaws, muscle rigidity, disability of  postural balance, difficulty 
in initiating willed movements as akinesia, and slowness of  
movement as bradykinesia [52, 53]. Many patients also suffer 
from cognitive impairment as PD progresses. The prevalence of  
PD is around 0.15% to 0.2% among the population, and 1% of  
the elders above 60 years old [54, 55].
The basal ganglia include the caudate nucleus, the putamen, 
the globus pallidus, and the subthalamic nucleus. Furthermore, 
the substantia nigra inside the midbrain structure also has the 
connection to the basal ganglia. The caudate and the putamen 
are responsible to receive the cortex input to the basal ganglia, 
which are also known as the striatum [56]. There are intrinsic and 
extrinsic fibers inside the basal ganglia, including the excitatory 
postsynaptic potential (EPSP) and the inhibitory postsynaptic 
potential (IPSP) types of  the synaptic activations. The intrinsic 
fibers mainly belong to the Acetylcholine (Ach) and Gamma-
aminobutyric acid (GABA) type, while the most importantly 
extrinsic fibers are the Dopamine (DA) type from the substantia 
nigra. Besides, the basal ganglia also has other input fibers 
including the Ach fibers from the thalamus, the Serotonin (5-HT) 
IPSP fibers from the red nucleus, and the glutamate IPSP fibers 
from the cortex.
Basically PD is the neurodegeneration among the DA fibers 
from the substantia nigra and input to the striatum [57]. Besides 
basal ganglia, the locus ceruleus, dorsal motor nucleus of  vagus, 
and even the sympathetic system may be also involved. The DA, 
Norepinephrine (NE), and 5-HT levels are significantly decreased 
among the damage area. Furthermore, the tyrosine hydroxylase 
as the key enzyme for DA synthesis is also deficient among the 
DA neurons. The pathology findings present the senile plaque, 
NFT, and Lewy bodies, which are the round-shaped eosinophilic 
granules with deeper-colored nucleus inside the neuron. The 
Lewy body is composed by the neurofilaments within 8-10 nm 
diameters in width, but it does not contain PHF.
The secondary PD may be caused by brain damages with 
various origins including long-term drug administrations and 
traumatic injuries. However, the etiology of  the primary PD 
still remains unclear. It involves various environmental factors 
including oxidative stress, DA metabolism, mitochondrial 
dysfunction, neuroinflammation, but rare genetic mutations have 
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been described [58-63]. The pathological processes leading to 
mitochondrial dysfunction among the DA neurons will result in 
the accumulation of  reactive oxygen species (ROS) and increase 
the risk of  oxidative stress, which may cause further damages to the 
related proteins, lipids and nucleic acids among the DA neurons 
[64-66]. Actually, the oxidative stress as the imbalance between 
the excessive free radicals and the intracellular antioxidant system 
is also extremely important in AD and other neurodegenerative 
pathogenesis [67, 68].
Currently there is not therapeutics available to decelerate the 
neurodegenerative progressions, and the medication is purely 
palliative. Therefore the therapeutic goal for PD is mainly on DA 
level enhancement, which may be achieved by the DA precursor, 
L-dihydroxyphenylalanine administrations. It may cross through 
the blood-brain barrier (BBB) and promote the remaining neurons 
in the substantia nigra for DA production. However, such therapy 
will become ineffective after all the DA neurons die in the later 
stage of  PD [69].
Huntington’s disease (HD)
In contrast to PD, HD is an autosomal dominant inherited 
neurodegenerative disorder with progressive and inevitably fatal 
syndrome. The prevalence of  HD is around 5 per 100,000 among 
the population [70]. It shares some similar clinical characteristics 
among ND including hyperkinesia, dyskinesia, dementia, 
cognitive impairment, and personality changes. However, the 
above symptoms would not appear until their adulthood. The 
typical sign of  HD is chorea corresponding to spontaneous and 
meaningless movements among various parts of  the body beyond 
control.
It is first described by the physician George Huntington in 
1872, and the related gene is identified as IT15 at short arm of  
chromosome 4 in 1993 [71]. IT15 will elongate with the repetitive 
sequence of  cytosine, adenosine, and guanine (CAG) [72]. 
Furthermore, the length of  CAG repetition will have influence on 
HD onset determination [73]. The pathological findings of  HD 
are mainly on the significant neuron loss in the caudate nucleus, 
putamen, and globus pallidus [74]. In addition, the cerebral cortex 
may also be included. The structural destructions of  basal ganglia 
and its loss of  output intrinsic fibers to the thalamus may induce 
movement disorders, including hyperkinesia and ballism as violent 
and flinging movement of  extremities. Similar to other ND, HD 
may lead to further mitochondrial dysfunction and the related 
oxidative stress [75].
Multiple Sclerosis (MS)
Traditionally MS is regarded as an inherited autoimmune disease 
with cell-mediated delayed hypersensitivity reactions. Patients 
suffering from MS often belong to the types of  human leukocyte 
antigen (HLA-typing) A3, B7 and DR2. BBB destructions 
with plasma cell hyperactivity and immunoglobulin G (IgG) 
overproduction outside the vessels are found around 40% to 50% 
MS patients in the early stage. In the acute MS known as Malburg 
type, the pathological findings present Balo’s concentric sclerosis 
at the cortex due to demyelinating [76], and Devic’s neuromyelitis 
optica at the spinal cord and the optical nerves. However, MS 
often presents chronic progressions with MS plaque sized from 
millimeters to centimeters due to myelin disappearance and glial 
cell proliferations. Recently MS is gradually regarded as a kind of  
ND due to ineffective response to the immunotherapies including 
immunosuppressive and immunomodulatory administrations 
[77]. Besides, MS also shows some similar pathogenesis pictures 
to ND. Recent pathological findings proved that T lymphocyte 
infiltration is still presented in the lesion with parenchymal loss 
[78-80]. In the molecular level, mitochondrial dysfunction due 
to inflammatory process is dominant in demyelination [81, 82].
Furthermore, kinase and phosphatase imbalance also result in 
cytoskeletal destructions [83]. The above facts may provide hints 
for further therapeutic development of  both MS and ND.
Amyotrophic lateral sclerosis (ALS)
ALS, also known as Lou Gehrig’s disease, is a life-threatening ND 
involved in the upper and lower motor neurons over the spinal 
cord, brain stem and the related motor cortex [84]. The mean 
onset age is about 55 years old, and the incidence is around 1-2 
per 100,000 per year with 3-5 years of  survival after diagnosis [85, 
86]. The pathological changes include neuronal apoptosis, fiber 
demyelination, and glial cell increases in the anterior and lateral 
corticospinal tract, which may lead to progressive paralysis. The 
etiology remains unclear, but 10% of  ALS is familial and relates 
to the genetic mutation of  antioxidant enzyme copper and zinc 
superoxide dismutase (SOD1) [87]. Both of  the sporadic and 
familial ALS may result from neuronal damage due to oxidative 
stress with free radical involvements [88-91]. Current potential 
therapeutics may include antioxidant, neuroregeneration and stem 
cell therapies [19, 92, 93].
Therapeutic developments of  ND
Currently there is no effective agent for ND patients and 
the commercially available drugs are mainly for palliative to 
decelerate the progressions. However, recent investigations 
provide indications for specific drug designs and therapeutic 
developments of  ND throughout the pathological mechanism 
and tissue engineering principles.
Oxidative stress modification
Oxidative stress is one of  the major subcellular mechanisms, which 
may produce free radicals, overwhelm the antioxidant system, 
and result in neuronal dysfunction and further axonal damage 
among various ND [94, 66]. It is often occur in mitochondrion 
among various subcellular organs and produce hydrogen peroxide 
due to oxygen consumption and adenosine triphosphate (ATP) 
generation [95]. The Coenzyme Q10 (2,3-dimethoxy-5-methyl-
6-decaprenil-1,4-benzoquinone), also regarded as CoQ10 or 
vitamin Q10, is an important antioxidant agent participating in 
various subcellular events [19]. It mainly accumulates in the inner 
membrane of  mitochondrion and inhibits lipid peroxidation [96, 
97]. Generally it may be obtained from daily diet, supplements, 
and absorbed in the small intestine. In addition, it may also be 
produced from tyrosine endogenously, especially in the organs 
with highly metabolic rate. A sixteen-month clinical study with 
80 patients presents 44% less functional decline in PD patients 
after oral administration of  CoQ101200 mg per day [98]. Muller 
also reported the positive results with moderate symptom 
improvements after 360 mg of  CoQ10 daily administrations 
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[99]. Furthermore, daily intake of  CoQ10 also improves learning 
and memory deficits by suppressing the oxidative stress and 
elevating the ATP level [100]. With 360 mg per day of  CoQ10 
administration for 2-8 weeks, the lactate level in the occipital 
cortex is suppressed [101], but it may return to the baseline value 
after stop administration. CoQ10 is also considered as the potential 
therapeutics of  ALS since the oxidative stress and mitochondrial 
dysfunction participate in ALS progressions [102].
Antibody therapy
 
Since complex physiological event involvements as proteinopathies 
among various types of  ND progressions, selective protein 
targeting has been considered as the reasonable approach in ND 
therapeutic development [103]. However, safety concern for such 
systemic immunotherapy should be carefully evaluated before 
further clinical trial. The US Food and Drug Administration 
(FDA) has approved several intravenous immunoglobulin (IVIg) 
injections as safe for several immune disorders. Such therapy may 
provide anti-Aβ antibodies to suppress Aβ fibril formation and 
enhance the Aβ clearance from the brain to avoid its neuronal 
toxicity [104-108]. In addition, the anti-Aβ antibodies present the 
ability to cross the BBB and may directly reach the lesion in central 
neural system (CNS). Several pilot clinical trials also reported 
the positive results for regular anti-Aβ antibody injections [109-
111]. Tauopathy is also regarded as another important target for 
immunotherapy development. The mutative tau may arouse NFT 
and lead to further frontotemporal dementia with parkinsonism 
(FTDP). The mouse model shows positive results after anti-tau 
immunotherapy by motor performance improvement [112]. The 
detected antibody in the transgenic mice also shows its ability to 
cross the BBB.
In the contrary, targeting mHtt protein immunotherapy reaches 
the difficulty due to its intracellular localization [113]. As the 
above descriptions, the mutative gene may encode proteins which 
lead to conformational changes toward monomers, oligomers, 
protofibrils, and the related fibrillar structures including A βplaques, 
Lewy bodies, α-synuclein and mHtt aggregates among various 
ND. Such proteinopathies provide the possibility for intrabody 
therapy [114, 115]. The intrabodies (iAbs) are the intracellular 
fragments which may recognize the specific antigen domains and 
provide the potential in further AD, PD, and HD therapeutics 
[103]. However, the efficiency of  these immunotherapies is not 
certain and further clinical trial arrangements are needed for both 
efficiency and safety confirm.
Neuroregenerative therapy
As the basic concept of  ND including neuronal damage, apoptosis 
and the related progressive dysfunctions, the neuroregenerative 
therapy is considered base on the principle of  tissue engineering, 
including neurorestoration as stem cell therapy, neurogenesis 
as neurotrophilins and growth factors, and neurotrophins [92, 
93, 116-119]. The adult neural stem cell has been proved its 
existence in the 1990s [120, 121], and present the possibility of  
neuroregeneration in various ND models [122]. However, the 
mammalian central nervous system (CNS) still presents in a limited 
capacity of  neurogenesis and proliferative property compared to 
other tissues. Most of  the neural stem cells or related progenitors 
may reside in the subventricular zone (SVZ), the lateral ventricular 
wall, and the subgranular zone of  the hippocampal dentate gyrus, 
which may provide the possibility for neurogenesis [123-125].
 
The natural occurring stem cells may be divided into two groups 
by their capacity of  differentiation including the totipotent, or the 
pluripotent embryonic stem cells (ESC), and the multipotent stem 
cells, such as fetal stem cells (FSC) and the adult stem cells. The 
ESCs present unlimited proliferative and differentiation capacities 
[126]. However, the applications are highly restricted due to 
various ethical concerns. Due to the challenges in neural stem 
cell extraction and the difficulty in mesenchymal stem cell (MSC) 
transdifferentiation, techniques for induced pluripotent stem 
cell (iPS) producing are developed via various reprogramming 
processes with specific transcription factors, such as Oct4, 
Sox2, Klf4, and c-Myc [127]. However, such therapy may face 
the challenges in safety concern for iPS induced teratomas [128], 
efficiency limitation in continuous stem cell delivery, and the 
invasive procedures in clinical practice to reach the central venous 
system. The above restrictions may limit the stem cell therapy 
in the life-threatening ND applications including ALS and MS 
[129]. In contrast, a clinical trial was conducted for AD patients 
with directly iPS delivery into CNS in 2005 [116], and reported 
positive results by both cognitive scales and positron emission 
tomography (PET) scanning after 22 months’ follow-up.
 
Neurotrophins and the related cytokines, such as Nerve Growth 
Factor (NGF), Brain-derived Nerve Factor (BDNF), neurotrophin 
3 (NT3), and neurotrophin 4 (NT4) also present the capacity to 
promote neuroregeneration in both normal CNS development 
and pathological aging [130-132]. However, these cytokines may 
systemically participate in various subcellular events throughout 
tropomyosin-related kinase (Trk) receptors and activate the 
relative signaling pathways. Safety concern with enough clinical 
trial evaluations are needed in such applications.
Intra-maxillary molecular releasing in applications 
of  ND therapeutics
The pathological process of  neurodegeneration presents as 
multiple cellular and subcellular event involvement, and that 
increases the difficulty on therapeutic development. Current ND 
therapies are majorly on symptom relief. The following situations 
should be taken into consideration in further therapeutic 
development:
1. Most ND present as the chronic progressive dysfunction 
without life-threatening properties, and the process may 
last for decades. For the above reason, regularly invasive 
procedures may be unbearable in applications to the 
ND patients, such as daily injections to prevent from 
neurodegeneration. That also means repeated surgical 
approaches including CNS delivery in stem cell therapy may 
be unacceptable in such ND patients.
2. Most of  the sufferings belong to the elderly, so that geriatrics 
becomes important in therapeutic considerations including 
cross-interactions and the related side effects of  other 
cardiovascular or antibiotic agents in ND drug delivery.
3. The pathogenesis of  ND present in the properties of  
proteinopathy including tauopathy, oxidative stress and 
neuroinflammation. That implies peptide, oligomer, 
and other functional macromolecular delivery may be 
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unavoidable in further therapeutic developments. However, 
such macromolecular absorption present unsteady, or even 
seems impossible directly byoral intake passing through the 
gastrointestinal (GI) tract. In contrast, regularly intravenous 
injection of  these macromolecules may become an invasive 
procedure with pain and irritations, which seems the paradox 
of  the first point.
4. The penetrative ability crossing through BBB may be much 
important in ND drug design considerations since the ability 
enhancement may lower down the relative side effects of  
ND administrations, especially in such chronic disease with 
the demand of  long-term and regular dosage administrations.
Despite the above restrictions, we may consider the optimal drug 
concentration in plasma to meet the ND therapeutic demand. As 
the progressively functional disorder with metabolic and other 
intrinsic origins, the demand of  ND curing dosage may present 
steady and continuous with a certain degree of  concentration 
rather than the massive and rapid drug releasing types in specific 
infectious applications.
Intra-maxillary molecular releasing via dental 
implant
The development of  dental implant has been lasting for decades 
and regarded as a mature procedure for tooth reconstructions 
since Dr. Brånemark announced the principle of  osseointegration 
in the 1970’s [133]. The basic principle of  dental implantology is 
shown in Figure 1(A). The tooth structure includes the outside 
enamel crown and the intra-bony root cementum, and its pain 
receptors are mainly from the pulp structure (a) inside the tooth, 
and the periodontal ligament (PDL) surrounding its outer surface 
and directly contact the bone marrow (b). Within dental implant 
placement after tooth loss, the above pain origins are both 
removed and offer a pathway for continuous molecular releasing 
and bio-sensing without painful sensations [134, 135]. Figure 1(B) 
presents the molecular releasing pathway from outside oral cavity 
passing through the titanium implant fixture to reach the inside 
bone marrow. Such pathway may provide some characteristics 
within the related advantages compared to the traditional drug 
delivery procedures as followings.
1. Compared to other traditional drug delivery procedures, the 
obvious advantage may be relative painless and continuous 
drug releasing throughout the whole process by such intra-
maxillary pathway.
2. Macromolecular or even cellular delivery with long-
term and continuous property is possible via such intra-
maxillary pathway. Moreover, the surrounding bone marrow 
environments may increase the initial stem cell survival 
rate compared to the intravenous injection type due to the 
blood flow velocity. However, we should notice that stem 
cell delivery into the maxillary bone marrow may face 
the difficulty crossing through BBB in ND therapeutic 
applications.
3. The intra-maxillary molecular releasing may avoid 
thrombolism and further risks of  stroke occur due to its 
bone marrow structure compared to other continuous 
venous drug releasing.
4. Multiple drug type delivery at the same time, which refers 
as combination therapy is also possible within this intra-
maxillary drug delivery pathway.
In contrast, it also presents some restrictions as following.
1. To maintain the stability of  the dental implant and avoid from 
further surrounding bony resorption, drug polymerization 
with slowly degraded properties to achieve molecular releasing 
Figure 1. The basic principle of  intra-maxillary molecular releasing throughout dental implant. (A) The pain receptors of  
the tooth are mainly from the pulp structure (a) and PDL (b). After implant placement, both (a) and (b) are replaced by (c) 
as the direct contact surface the outside bone marrow, and offer a painless pathway for both drug releasing and bio-sens-
ing. (B) The molecular pathway from the outside oral cavity passing through the implant fixture to reach the inside bone       
marrow.
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is needed. That implies rapid and massive drug releasing is 
impossible throughout such drug delivery pathway. However, 
as multiple proteinopathy involvements including metabolic, 
neuroinflammation and other genetic mutative events, the 
ND therapeutics may require the continuous and steady drug 
releasing type rather than the rapid onset ones.
2. The types of  the loading drugs should be carefully evaluated 
to avoid further destructions of  the osseointegrative implant 
structure. For example, the low pH value molecules with 
immuno-induced properties may be an inappropriate target 
for intra-maxillary releasing.
For further detail discussions in such intra-maxillary drug delivery 
pathway and its applications of  ND therapeutics, we will review 
the principle of  pharmacokinetics.
Pharmacokinetics in intra-maxillary molecular 
releasing
After administrations of  the drug loading dosages via various 
pathways including oral intake, intravenous, intramuscular, 
subcutaneous, and so on, the concentration in plasma may 
gradually increase to reach the maximum value (Cmax), and then 
decay slowly due to the intrinsic eliminative process. Figure 
2(A) plots the concentration curve throughout the whole 
administration process, and area under the curve corresponds 
to the bioavailability. Once when the concentration presents 
higher than the minimal effective concentration (MEC) regarded 
as onset of  the loading drug, it will lead to further meaningful 
biological functions until the concentration lower than MEC.
The period when the loading concentration presents higher than 
MEC may correspond to the drug duration. However, it should 
remain under the minimal toxic concentration (MTC) throughout 
the whole drug loading process. Otherwise the drug toxicities and 
other significant side effects may occur.
The drug design of  the rapid onset or sustained releasing types 
may accords to the above principles, which shows in the Figure 
2(B). The drug concentration of  the rapid onset type may 
increase immediately higher than MEC after administration, but 
maintain in a relative short period and degrade soon. In contrast, 
the sustained type may present as slower onset time with longer 
period remaining above the MEC. However, since intra-maxillary 
drug releasing presents as the slowly polymeric dissolved type, 
its concentration in plasma may maintain in a certain level and 
last for a relative long period compared to other drug delivery 
pathways, which may present more benefits in further ND 
therapeutic applications.
Due to slowly and macro-molecularly releasing properties, 
intra-maxillary pathway may have potential in assistance to ND 
therapeutic development. Furthermore, the combination therapy 
within nanotechnology may enhance the efficiency and reduce 
the relative side effects, including polymer-drug conjugates, 
nanoemulsions, dendrimers, micelles, liposomes, solid lipid and 
polymeric nanoparticles [136-138]. Current nanotechnology 
may even improve the permeability to penetrate the BBB and 
enhance its concentration in cerebrospinal fluid (CSF) [139].
Personalized drug design according to the inter-individual genetic 
variability passing through pharmacogenomics may also provide 
another approach to enhance the drug efficiency [140]. The above 
developments may be much important especially in long-term 
administration for ND management to improve the prognosis 
and promote their life qualities.
Conclusion
Neurodegeneration is currently regarded as a chronic and 
irreversible process lasting from years to decades. The pathological 
demyelination, atrophic changes and the related neuronal 
apoptosis may lead to progressively cognitive impairment and 
multiple dysfunctions. Due to its specific properties and the 
related geriatric concerns, the therapeutic design and treatment 
investigation should be delicately evaluated from research to 
clinical practice to eliminate the regularly invasive procedures and 
reduce the side effects. The intra-maxillary molecular releasing 
Figure 2. (A) presents the basic pharmacokinetic curve during the whole drug administrative process. The concentration 
higher than MEC will lead to clinical benefits of  the drug loading. (B) shows various loading curves via different pathways, 
while intra-maxillary drug releasing type may maintain in a relative continuous and steady level.
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provides a long-term continuous and relative painless drug 
delivery pathway to achieve macromolecular or even cellular 
delivery into maxilla throughout the dental implant. Since dental 
implantology has become a mature technique, the combination of  
the specific nanomedicine and such newly drug delivery pathway 
may be appropriate for further ND therapeutic applications. 
However, such device is still immature and multi-disciplinary 
technology may be involved for further improvement including 
complementary metal-oxide-semiconductor (CMOS) technology, 
chemical engineering, pharmacokinetics, therapeutics, medicine, 
and dentistry. Fortunately, such pathway seems practicable not 
only theoretically, but also in the medical and dental aspects. As 
the promotion of  life expectance in the beginning of  21st century, 
ND management may become critical and urgent in geriatric 
development.
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